Novel treatment options for epilepsy: Focus on perampanel

Franco, Valentina; Crema, Francesca; Iudice, Alfonso; Zaccara, Gaetano; Grillo, Elisabetta

doi:10.1016/j.phrs.2012.12.006

Cited by 71 publications

(64 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on population PK modeling, perampanel apparent clearance was 17% lower in female than in male participants not receiving concomitant EIAEDs, and it remained somewhat lower with concomitant EIAEDs, implying greater perampanel systemic exposure in females. The PK of perampanel includes a half‐life of ~105 h as well as rapid and almost complete absorption following oral administration 7, 16. Physiologic gender differences may contribute to the lower perampanel CL/F in female patients and may be associated with greater perampanel systemic exposure.…”

Section: Discussionmentioning

confidence: 99%

“…Perampanel is approved in ≥40 countries, including the United States and the European Union, for adjunctive treatment of partial seizures, with or without secondarily generalized seizures, in patients with epilepsy who are ≥12 years of age, and in Canada for patients ≥18 years of age. The pharmacokinetic (PK) profile of perampanel includes a half‐life of ~105 h as well as rapid and almost complete absorption following oral administration 7. In addition, perampanel plasma concentrations increase in direct proportion to dose 7…”

mentioning

confidence: 99%

See 1 more Smart Citation

Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures

et al. 2015

View full text Add to dashboard Cite

SummaryThe antiepileptic drug (AED) perampanel is approved in ≥40 countries as adjunctive therapy for drug‐resistant partial seizures in patients with epilepsy. This post hoc analysis of pooled data from three phase III, double‐blind, randomized studies of perampanel examines between‐gender differences in perampanel efficacy and safety. Of the 1,478 subjects in the pooled analysis (719 male, 759 female), 1,109 were included in the pharmacokinetic/pharmacodynamic analysis. Perampanel oral clearance was 17% lower in female than in male patients not receiving enzyme‐inducing AEDs. Pooled efficacy analysis revealed that seizure frequency was reduced with perampanel treatment regardless of gender; a greater numerical reduction in seizure frequency and increased responder rates occurred in female participants at perampanel doses of 4, 8, and 12 mg. Tolerability was similar between groups, although common adverse events such as dizziness and headache occurred more frequently in female subjects. Modest elevations in perampanel exposure in female patients may result in meaningful between‐gender differences in efficacy and safety; therefore, dosing should be individualized and clinical response monitored.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Открытые обсервационные исследования [35,36,38], а также исследования длительной терапии [9,18,19] также продемонстрировали благоприятные пока-затели эффективности и безопасности при длительной терапии и длительное сохранение терапевтического эффекта.…”

Section: Ch I Ld Neurology R U S S I a N J O U R N A L O Funclassified

“…Перампа-нел -мощный высокоселективный неконкурентный ингибитор ионотропных AMPA-рецепторов постсинап-тических мембран нейронов на уровне неокортекса и гиппокампа [6,9,26,41]. По мнению многих авторов, перампанел -первый АЭП со специфическим дейст-вием на обмен глутамата (опосредованное глутаматом возбуждение в ЦНС), эффективность и переносимость которого при резистентных фокальных приступах были доказаны в клинических исследованиях III фазы [13, 17-21, 27, 28, 31].…”

unclassified

“…Период полувыве-дения составляет около 52-129 ч (в среднем 105 ч) после однократного приема и 66-90 ч после много-кратного приема, это позволяет принимать препарат 1 раз в день (что очень удобно для пациентов и повы-шает комплаентность терапии). Пиковая концентра-ция в плазме достигается через 0,25-2 ч после приема препарата [9,24].…”

unclassified

See 1 more Smart Citation